APO Research
Talk to an analyst

APO RESEARCH · REPORT

Inactivated Influenza Virus Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Inactivated Influenza Virus Vaccine Market Outlook and Growth Opportunities 2026

30 December 2025208 pages

Choose your research edition.

Industry ResearchInactivated Influenza Virus Vaccine Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Inactivated Influenza Virus Vaccine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Inactivated Influenza Virus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inactivated Influenza Virus Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Inactivated Influenza Virus Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Inactivated Influenza Virus Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Inactivated Influenza Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Inactivated Influenza Virus Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Inactivated Influenza Virus Vaccine market include CSL, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Johnson & Johnson, Mylan, Lanzhou Institute of Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd and Jiangsu Jindik Biotechnology Co., Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Inactivated Influenza Virus Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Inactivated Influenza Virus Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Inactivated Influenza Virus Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Inactivated Influenza Virus Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Inactivated Influenza Virus Vaccine Segment by Company

CSL

Zhejiang Tian Yuan Biopharmaceutical Co., Ltd

Changchun Institute of Biological Products Co., Ltd

Shanghai Institute of Biological Products Co., Ltd

Johnson & Johnson

Mylan

Lanzhou Institute of Biological Products Co., Ltd

Jiangsu Kangrun Biotechnology Co., Ltd

Jiangsu Jindik Biotechnology Co., Ltd

Pfizer

Hualan Bio Vaccines Co., Ltd

GSK

Dalian Yalifeng Biopharmaceutical Co., Ltd

Beijing Kexing Biological Products Co., Ltd

Emmi Chengxin Biopharmaceutical Co., Ltd

AstraZeneca

Sanofi Pasteur

Inactivated Influenza Virus Vaccine Segment by Type

Whole Virus Vaccine

Subunit Vaccine

Inactivated Influenza Virus Vaccine Segment by Application

Hospital

Clinic

Inactivated Influenza Virus Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Inactivated Influenza Virus Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Inactivated Influenza Virus Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Inactivated Influenza Virus Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Inactivated Influenza Virus Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Inactivated Influenza Virus Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Inactivated Influenza Virus Vaccine industry.

Chapter 3: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Inactivated Influenza Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Inactivated Influenza Virus Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Inactivated Influenza Virus Vaccine Industry Trends Table 2. Inactivated Influenza Virus Vaccine Industry Drivers Table 3. Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges Table 4. Inactivated Influenza Virus Vaccine Industry Restraints Table 5. Global Inactivated Influenza Virus Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Inactivated Influenza Virus Vaccine Revenue Share by Company (2021-2026) Table 7. Global Inactivated Influenza Virus Vaccine Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Inactivated Influenza Virus Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Inactivated Influenza Virus Vaccine Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Inactivated Influenza Virus Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Inactivated Influenza Virus Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Inactivated Influenza Virus Vaccine Company, Product Type & Application Table 13. Global Inactivated Influenza Virus Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Inactivated Influenza Virus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Whole Virus Vaccine Table 18. Significant Companies of Subunit Vaccine Table 19. Global Inactivated Influenza Virus Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Inactivated Influenza Virus Vaccine Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Inactivated Influenza Virus Vaccine Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Inactivated Influenza Virus Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Inactivated Influenza Virus Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Inactivated Influenza Virus Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Inactivated Influenza Virus Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Inactivated Influenza Virus Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Inactivated Influenza Virus Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Inactivated Influenza Virus Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Global Inactivated Influenza Virus Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Inactivated Influenza Virus Vaccine Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Inactivated Influenza Virus Vaccine Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Inactivated Influenza Virus Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Inactivated Influenza Virus Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Inactivated Influenza Virus Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Inactivated Influenza Virus Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Inactivated Influenza Virus Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Inactivated Influenza Virus Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Inactivated Influenza Virus Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Inactivated Influenza Virus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Inactivated Influenza Virus Vaccine Sales by Region (2021-2026) & (K Units) Table 43. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Inactivated Influenza Virus Vaccine Sales by Region (2027-2032) & (K Units) Table 45. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Inactivated Influenza Virus Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Inactivated Influenza Virus Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Inactivated Influenza Virus Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Inactivated Influenza Virus Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Inactivated Influenza Virus Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Inactivated Influenza Virus Vaccine Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Inactivated Influenza Virus Vaccine Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Inactivated Influenza Virus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Inactivated Influenza Virus Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 56. Global Inactivated Influenza Virus Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 58. Global Inactivated Influenza Virus Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Inactivated Influenza Virus Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Inactivated Influenza Virus Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Inactivated Influenza Virus Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Inactivated Influenza Virus Vaccine Sales Value Market Share by Country (2027-2032) Table 63. CSL Company Information Table 64. CSL Business Overview Table 65. CSL Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. CSL Inactivated Influenza Virus Vaccine Product Portfolio Table 67. CSL Recent Development Table 68. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information Table 69. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview Table 70. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 72. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Development Table 73. Changchun Institute of Biological Products Co., Ltd Company Information Table 74. Changchun Institute of Biological Products Co., Ltd Business Overview Table 75. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 77. Changchun Institute of Biological Products Co., Ltd Recent Development Table 78. Shanghai Institute of Biological Products Co., Ltd Company Information Table 79. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 80. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 82. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 83. Johnson & Johnson Company Information Table 84. Johnson & Johnson Business Overview Table 85. Johnson & Johnson Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio Table 87. Johnson & Johnson Recent Development Table 88. Mylan Company Information Table 89. Mylan Business Overview Table 90. Mylan Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Mylan Inactivated Influenza Virus Vaccine Product Portfolio Table 92. Mylan Recent Development Table 93. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 94. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 95. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 97. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 98. Jiangsu Kangrun Biotechnology Co., Ltd Company Information Table 99. Jiangsu Kangrun Biotechnology Co., Ltd Business Overview Table 100. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 102. Jiangsu Kangrun Biotechnology Co., Ltd Recent Development Table 103. Jiangsu Jindik Biotechnology Co., Ltd Company Information Table 104. Jiangsu Jindik Biotechnology Co., Ltd Business Overview Table 105. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 107. Jiangsu Jindik Biotechnology Co., Ltd Recent Development Table 108. Pfizer Company Information Table 109. Pfizer Business Overview Table 110. Pfizer Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Pfizer Inactivated Influenza Virus Vaccine Product Portfolio Table 112. Pfizer Recent Development Table 113. Hualan Bio Vaccines Co., Ltd Company Information Table 114. Hualan Bio Vaccines Co., Ltd Business Overview Table 115. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 117. Hualan Bio Vaccines Co., Ltd Recent Development Table 118. GSK Company Information Table 119. GSK Business Overview Table 120. GSK Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. GSK Inactivated Influenza Virus Vaccine Product Portfolio Table 122. GSK Recent Development Table 123. Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information Table 124. Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview Table 125. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 127. Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Development Table 128. Beijing Kexing Biological Products Co., Ltd Company Information Table 129. Beijing Kexing Biological Products Co., Ltd Business Overview Table 130. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 132. Beijing Kexing Biological Products Co., Ltd Recent Development Table 133. Emmi Chengxin Biopharmaceutical Co., Ltd Company Information Table 134. Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview Table 135. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 137. Emmi Chengxin Biopharmaceutical Co., Ltd Recent Development Table 138. AstraZeneca Company Information Table 139. AstraZeneca Business Overview Table 140. AstraZeneca Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio Table 142. AstraZeneca Recent Development Table 143. Sanofi Pasteur Company Information Table 144. Sanofi Pasteur Business Overview Table 145. Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio Table 147. Sanofi Pasteur Recent Development Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Inactivated Influenza Virus Vaccine Distributors List Table 151. Inactivated Influenza Virus Vaccine Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Inactivated Influenza Virus Vaccine Product Image Figure 2. Global Inactivated Influenza Virus Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Inactivated Influenza Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Inactivated Influenza Virus Vaccine Sales (2021-2032) & (K Units) Figure 5. Global Inactivated Influenza Virus Vaccine Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Inactivated Influenza Virus Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Whole Virus Vaccine Image Figure 10. Subunit Vaccine Image Figure 11. Global Inactivated Influenza Virus Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Inactivated Influenza Virus Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Inactivated Influenza Virus Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Inactivated Influenza Virus Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Inactivated Influenza Virus Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Inactivated Influenza Virus Vaccine Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Global Inactivated Influenza Virus Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Inactivated Influenza Virus Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Inactivated Influenza Virus Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Inactivated Influenza Virus Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Inactivated Influenza Virus Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Inactivated Influenza Virus Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Inactivated Influenza Virus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Inactivated Influenza Virus Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Inactivated Influenza Virus Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Inactivated Influenza Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Inactivated Influenza Virus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Inactivated Influenza Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Inactivated Influenza Virus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Inactivated Influenza Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Inactivated Influenza Virus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Inactivated Influenza Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Inactivated Influenza Virus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Inactivated Influenza Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Inactivated Influenza Virus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Inactivated Influenza Virus Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Inactivated Influenza Virus Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Whole Virus Vaccine
  • Subunit Vaccine
Applications
  • Hospital
  • Clinic
Companies covered
  • CSL
  • Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
  • Changchun Institute of Biological Products Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd
  • Johnson & Johnson
  • Mylan
  • Lanzhou Institute of Biological Products Co., Ltd
  • Jiangsu Kangrun Biotechnology Co., Ltd
  • Jiangsu Jindik Biotechnology Co., Ltd
  • Pfizer
  • Hualan Bio Vaccines Co., Ltd
  • GSK
  • Dalian Yalifeng Biopharmaceutical Co., Ltd
  • Beijing Kexing Biological Products Co., Ltd
  • Emmi Chengxin Biopharmaceutical Co., Ltd
  • AstraZeneca
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Inactivated Influenza Virus Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Inactivated Influenza Virus Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Inactivated Influenza Virus Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Inactivated Influenza Virus Vaccine Market Dynamics
  1. 2.1 Inactivated Influenza Virus Vaccine Industry Trends
  2. 2.2 Inactivated Influenza Virus Vaccine Industry Drivers
  3. 2.3 Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges
  4. 2.4 Inactivated Influenza Virus Vaccine Industry Restraints
3 Inactivated Influenza Virus Vaccine Market by Company
  1. 3.1 Global Inactivated Influenza Virus Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Inactivated Influenza Virus Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Inactivated Influenza Virus Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Inactivated Influenza Virus Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Inactivated Influenza Virus Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Inactivated Influenza Virus Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Inactivated Influenza Virus Vaccine Company Product Type and Application
  8. 3.8 Global Inactivated Influenza Virus Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Inactivated Influenza Virus Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Inactivated Influenza Virus Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Inactivated Influenza Virus Vaccine Market by Type
  1. 4.1 Inactivated Influenza Virus Vaccine Type Introduction
  2. 4.1.1 Whole Virus Vaccine
  3. 4.1.2 Subunit Vaccine
  4. 4.2 Global Inactivated Influenza Virus Vaccine Sales Volume by Type
  5. 4.2.1 Global Inactivated Influenza Virus Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Inactivated Influenza Virus Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Inactivated Influenza Virus Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Inactivated Influenza Virus Vaccine Sales Value by Type
  9. 4.3.1 Global Inactivated Influenza Virus Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Inactivated Influenza Virus Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Inactivated Influenza Virus Vaccine Sales Value Share by Type (2021-2032)
5 Inactivated Influenza Virus Vaccine Market by Application
  1. 5.1 Inactivated Influenza Virus Vaccine Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.2 Global Inactivated Influenza Virus Vaccine Sales Volume by Application
  5. 5.2.1 Global Inactivated Influenza Virus Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Inactivated Influenza Virus Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Inactivated Influenza Virus Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Inactivated Influenza Virus Vaccine Sales Value by Application
  9. 5.3.1 Global Inactivated Influenza Virus Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Inactivated Influenza Virus Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Inactivated Influenza Virus Vaccine Sales Value Share by Application (2021-2032)
6 Inactivated Influenza Virus Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Inactivated Influenza Virus Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Inactivated Influenza Virus Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Inactivated Influenza Virus Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Inactivated Influenza Virus Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Inactivated Influenza Virus Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Inactivated Influenza Virus Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Inactivated Influenza Virus Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Inactivated Influenza Virus Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Inactivated Influenza Virus Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Inactivated Influenza Virus Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Inactivated Influenza Virus Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Inactivated Influenza Virus Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Inactivated Influenza Virus Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Inactivated Influenza Virus Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Inactivated Influenza Virus Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Inactivated Influenza Virus Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Inactivated Influenza Virus Vaccine Sales Value Share by Country, 2025 VS 2032
7 Inactivated Influenza Virus Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Inactivated Influenza Virus Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Inactivated Influenza Virus Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Inactivated Influenza Virus Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Inactivated Influenza Virus Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Inactivated Influenza Virus Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Inactivated Influenza Virus Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Inactivated Influenza Virus Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Inactivated Influenza Virus Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Inactivated Influenza Virus Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Inactivated Influenza Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Inactivated Influenza Virus Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 CSL
  2. 8.1.1 CSL Company Information
  3. 8.1.2 CSL Business Overview
  4. 8.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio
  6. 8.1.5 CSL Recent Developments
  7. 8.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
  8. 8.2.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information
  9. 8.2.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview
  10. 8.2.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  12. 8.2.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
  13. 8.3 Changchun Institute of Biological Products Co., Ltd
  14. 8.3.1 Changchun Institute of Biological Products Co., Ltd Company Information
  15. 8.3.2 Changchun Institute of Biological Products Co., Ltd Business Overview
  16. 8.3.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  18. 8.3.5 Changchun Institute of Biological Products Co., Ltd Recent Developments
  19. 8.4 Shanghai Institute of Biological Products Co., Ltd
  20. 8.4.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  21. 8.4.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  22. 8.4.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  24. 8.4.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Mylan
  32. 8.6.1 Mylan Company Information
  33. 8.6.2 Mylan Business Overview
  34. 8.6.3 Mylan Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio
  36. 8.6.5 Mylan Recent Developments
  37. 8.7 Lanzhou Institute of Biological Products Co., Ltd
  38. 8.7.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  39. 8.7.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  40. 8.7.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  42. 8.7.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  43. 8.8 Jiangsu Kangrun Biotechnology Co., Ltd
  44. 8.8.1 Jiangsu Kangrun Biotechnology Co., Ltd Company Information
  45. 8.8.2 Jiangsu Kangrun Biotechnology Co., Ltd Business Overview
  46. 8.8.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  48. 8.8.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
  49. 8.9 Jiangsu Jindik Biotechnology Co., Ltd
  50. 8.9.1 Jiangsu Jindik Biotechnology Co., Ltd Company Information
  51. 8.9.2 Jiangsu Jindik Biotechnology Co., Ltd Business Overview
  52. 8.9.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  54. 8.9.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
  55. 8.10 Pfizer
  56. 8.10.1 Pfizer Company Information
  57. 8.10.2 Pfizer Business Overview
  58. 8.10.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio
  60. 8.10.5 Pfizer Recent Developments
  61. 8.11 Hualan Bio Vaccines Co., Ltd
  62. 8.11.1 Hualan Bio Vaccines Co., Ltd Company Information
  63. 8.11.2 Hualan Bio Vaccines Co., Ltd Business Overview
  64. 8.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  66. 8.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments
  67. 8.12 GSK
  68. 8.12.1 GSK Company Information
  69. 8.12.2 GSK Business Overview
  70. 8.12.3 GSK Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio
  72. 8.12.5 GSK Recent Developments
  73. 8.13 Dalian Yalifeng Biopharmaceutical Co., Ltd
  74. 8.13.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information
  75. 8.13.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview
  76. 8.13.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  78. 8.13.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
  79. 8.14 Beijing Kexing Biological Products Co., Ltd
  80. 8.14.1 Beijing Kexing Biological Products Co., Ltd Company Information
  81. 8.14.2 Beijing Kexing Biological Products Co., Ltd Business Overview
  82. 8.14.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  84. 8.14.5 Beijing Kexing Biological Products Co., Ltd Recent Developments
  85. 8.15 Emmi Chengxin Biopharmaceutical Co., Ltd
  86. 8.15.1 Emmi Chengxin Biopharmaceutical Co., Ltd Company Information
  87. 8.15.2 Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview
  88. 8.15.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  90. 8.15.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
  91. 8.16 AstraZeneca
  92. 8.16.1 AstraZeneca Company Information
  93. 8.16.2 AstraZeneca Business Overview
  94. 8.16.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio
  96. 8.16.5 AstraZeneca Recent Developments
  97. 8.17 Sanofi Pasteur
  98. 8.17.1 Sanofi Pasteur Company Information
  99. 8.17.2 Sanofi Pasteur Business Overview
  100. 8.17.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio
  102. 8.17.5 Sanofi Pasteur Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Inactivated Influenza Virus Vaccine Value Chain Analysis
  2. 9.1.1 Inactivated Influenza Virus Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Inactivated Influenza Virus Vaccine Sales Mode & Process
  6. 9.2 Inactivated Influenza Virus Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Inactivated Influenza Virus Vaccine Distributors
  9. 9.2.3 Inactivated Influenza Virus Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst